In 2015, ATNAHS acquired the global rights to one of the most renowned brands in recent decades. Naprosyn (naproxen) from Roche.
Naprosyn (naproxen) is a non-steroidal inflammatory drug (NSAID) indicated as an oral treatment for rheumatoid arthritis, osteoarthrosis (degenerative arthritis), ankylosing spondylitis, acute gout, acute musculoskeletal disorders, juvenile rheumatoid arthritis and dysmenorrhoea.1 Naprosyn (naproxen) was first launched in the UK in 1976 by Syntex.2
By 1987, worldwide sales of Naprosyn and Anaprox were estimated at nearly $600 million.3 Twenty years later, the Naprosyn molecule naproxen was one of the top 100 medicines most prescribed in the US with 11.9 million prescriptions.4
In the UK, in 2019, naproxen sales were ranked 37th with 6.9 million prescriptions, with a market value of £93.3 million.5
Global sales of NSAIDs (including Naprosyn) are forecast to reach $24.35 billion by 2027 exhibiting a compound annual growth rate (CAGR) of 5.8% during this period.6 Of these global NSAID sales, naproxen is forecast to represent 5% of the market.7
All of the information presented above is factual historical information that is available in the public domain and is included in good faith. It is not the intention to make any new or fresh claims nor to be promotional for the product in question.
For further product information please follow this link to the relevant product page on this site.